To The Moon

One share price, two completely different stories

I rarely see a stock where Wall Street and the market appear to be reading entirely different scripts.

Hims & Hers Health trades around $33, yet the consensus target from 13 analysts sits between $28 and $30, implying roughly 13% downside. At the bullish end, Canaccord Genuity recently lifted its target to $40. At the bearish end, one analyst believes the shares are worth just $21. That's a spread of more than 90% between the highest and lowest targets, and it tells me one thing above all else: nobody can agree what this business is actually worth.

The market and Wall Street rarely disagree this dramatically.

Perhaps the market still knows something analysts don't. Or perhaps investors have simply fallen in love with a compelling narrative.

The shares rallied roughly 67% during the second quarter alone. Yet only months earlier, Novo Nordisk's patent lawsuit erased almost 20% of Hims' market value in a single trading session before an eventual settlement turned yesterday's courtroom opponent into today's distribution partner.

With the FDA's Peptide Compounding Advisory Committee meeting on 23–24 July now just days away, investors may soon discover which camp has been reading the script correctly.

From courtroom enemies to commercial partners

The first half of 2026 has been extraordinary, even by healthcare standards.

In February, Novo Nordisk sued Hims over compounded semaglutide, triggering a sharp sell-off as investors feared the company's fastest-growing opportunity was about to disappear.

A month later, the two companies stunned the market by settling the dispute and announcing a commercial partnership, allowing Hims to distribute Novo's FDA-approved GLP-1 medicines through its platform.

Corporate America rarely produces plot twists this dramatic. Netflix would probably reject the script for being too implausible.

The obvious interpretation is that Hims escaped a legal headache. I think the more interesting possibility is that Novo concluded partnering with Hims was ultimately more profitable than trying to stop the consumer demand Hims had already created.

That is a very different strategic outcome.

The financials reveal a business in transition

The latest financial results tell two stories, depending on which numbers attract your attention first.

Trailing twelve-month revenue reached $2.37 billion, rising 32.8% year-on-year and continuing an extraordinary expansion from just $272 million in 2021. Few healthcare businesses sustain that level of organic momentum for several years.

Profitability, however, has become noticeably less impressive.

Trailing net income has slipped to a $13.2 million loss after the company generated profits exceeding $125 million during both 2024 and 2025. Operating margin has also moved back into negative territory at -1.3%.

Viewed in isolation, those figures suggest the business is moving backwards.

Cash flow tells a rather different story.

Operating cash flow remains robust at approximately $280 million, while free cash flow remains positive at almost $80 million, despite increased investment and acquisition spending.

Accounting profits have weakened, but the business continues generating meaningful cash. Investors often obsess over earnings while cash quietly pays the bills.

Evidence that the pivot is already working

The market's optimism isn't based purely on hope.

Volatility isn't noise—it's become the investment thesis

Following the Novo partnership, sales growth accelerated from mid-single digits in April to the high teens by June, suggesting customers embraced authorised branded therapies more quickly than many expected.

That trend also appears in customer economics.

Subscribers increased to 2.58 million, but the more revealing statistic is that monthly revenue per average subscriber climbed from $65 to $83 over the past year.

That tells me Hims is becoming better at selling additional healthcare services to existing customers rather than relying solely on finding new ones.

It is a subtle shift, but an important one. Customer acquisition is expensive. Expanding the relationship with customers you already have is usually far more profitable.

The company increasingly resembles a consumer healthcare platform rather than simply an online prescription service.

The FDA could become friend or foe

The FDA meeting dominates the investment debate for understandable reasons.

If regulators formally recommend tighter restrictions on compounded peptides, one of the categories that fuelled Hims' rapid growth becomes significantly less attractive.

That is the obvious risk.

The less obvious possibility is that tighter regulation actually strengthens the company's long-term strategy.

Hims has already begun pivoting towards distributing FDA-approved branded medicines. If compounded alternatives become harder to obtain, patients may naturally migrate towards approved products sold through trusted platforms.

Ironically, the catalyst bears fear most could reinforce the strategic direction bulls have been celebrating.

I am not suggesting the transition will be painless. I am suggesting the market may be underestimating how different Hims looks today compared with six months ago.

This is becoming a proxy war with Big Pharma

Most investors still frame the competitive landscape as Hims versus other telehealth companies.

I think they're looking in the wrong direction.

The real contest is increasingly between pharmaceutical giants and the digital platforms that own the patient relationship.

Eli Lilly is building its own direct-to-consumer ecosystem for obesity treatments. Novo Nordisk has chosen a different path by partnering with Hims after first taking it to court.

That makes Hims something of a live experiment.

Do large pharmaceutical companies crush digital disruptors, compete directly with them or eventually conclude it is cheaper to sell through them?

For now, Novo appears to have chosen the third option.

There is, however, a trade-off that I don't think receives enough attention. Hims is gradually replacing one risk with another. Regulatory uncertainty may be fading, but supplier concentration is quietly increasing. If future GLP-1 growth depends heavily on a handful of pharmaceutical partners, pricing power inevitably shifts towards the drug manufacturers.

In other words, the Novo partnership reduces legal uncertainty while increasing commercial dependence. That's hardly a fatal flaw, but it is a subtle shift in the investment case that deserves more attention.

It's also why the Eucalyptus acquisition matters more than it first appears. Expanding internationally gives Hims another avenue for growth just as regulatory scrutiny intensifies in the United States, reducing its reliance on any single market or product category. While the spotlight naturally falls on GLP-1 medicines, geographic diversification could prove just as valuable over the longer term.

Every advantage arrives carrying a new risk

The valuation leaves little room for indigestion

This is where optimism collides with arithmetic.

The shares trade on a forward price-to-earnings multiple above 60, a price-to-free-cash-flow ratio approaching 95 and a price-to-book multiple close to 17.

Those are demanding valuations by any conventional measure.

Supporters argue investors are valuing tomorrow's healthcare platform rather than today's earnings profile.

Critics argue investors are paying tomorrow's price using yesterday's excitement.

Both camps have a point.

The move away from high-margin compounded medicines towards branded pharmaceutical distribution is also likely to compress margins over time. Revenue growth alone may therefore flatter future earnings potential.

At these valuations, investors are still paying a premium for continued execution. The market is assuming Hims can successfully navigate the transition from compounded medicines to a broader consumer healthcare platform while sustaining exceptional growth. That may prove achievable, but it leaves relatively little room for disappointment.

Capital rarely lies, even when opinions do

Wall Street or the market?

I understand why Wall Street remains cautious while the market continues charging ahead.

Operationally, Hims is executing impressively. Revenue growth remains exceptional, customer monetisation is improving, cash generation is healthy and the partnership with Novo has transformed what looked like an existential legal threat into a potentially powerful strategic advantage.

Yet the shares already reflect a healthy degree of optimism.

Ultimately, this is less a debate about whether Hims is a good business than about how much of that success is already reflected in the share price.

Wall Street says it is worth around $28 to $30. The market says closer to $33. Within days, the FDA may provide the next piece of evidence.

Eventually, either continued execution will persuade analysts to lift their targets closer to the current share price, or the market will decide it has become a little too optimistic. The FDA's upcoming decision could provide the next important clue as to which path unfolds first.

@TigerStars @Daily_Discussion @Tiger_comments @Tiger_SG @Tiger_Earnings @TigerClub @TigerWire